Stockreport

First Results of New Data of ABRAXANE in Combination with Atezolizumab Presented at ESMO 2018

CELGENE  (CELG) 
Last celgene earnings: 10/31 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.celgene.com
PDF IMpassion130 reports first positive Phase III study results for a chemotherapy/immunotherapy (ABRAXANE plus atezolizumab) combination in first-line metas [Read more]